THIS IS A WHITE HOT AREA OF BIOTECHNOLOGY !
GTHA – GeneThera, Inc.
Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
GeneThera, Inc. (GTHA) updated its shareholders with a release announcing the continuation of work done earlier by the Company on RNA Interference (RNAi) in its Colorado laboratory.
RNAi has revolutionized how biomedical science is done. Researchers can switch off genes in cells cultured in a laboratory dish to understand what they do in people – in a fraction of the time and cost it used to take studying the same thing in specially bred animals. There’s a huge potential for curing and identifying the cause of human disease and these opportunities just didn’t exist a few years ago.
The emerging area of RNA interference, or RNAi, moved into the limelight on Oct. 30 when Merck & Co Inc agreed to pay $1.1 billion for U.S. biotech specialist Sirna Therapeutics Inc , nearly double its prevailing stock price.
RNAi involves “silencing” genes and is seen as having the potential to produce promising new treatments for diseases such as cancer, AIDS and blindness.
The technology is based on manipulating ribonucleic acid — the genetic messenger of a cell — to interfere with or “silence” targeted genes in order to prevent the formation of proteins that can cause diseases.
“Momentum for biotech companies and stocks continues to build…in this final quarter of the year on a high note, with one of its best monthly performances of 2006,” said Steven Burrill, chief executive of Burrill & Co, a San Francisco, USA-based global life sciences group the principal activities of which are in venture capital, merchant banking and media.
“Biotech is riding a wave of heightened investor enthusiasm driven by an increase in M&A activity, significant clinical data reported broadly and excellent third-quarter financial reports,” Mr Burrill added.
“Historically, the fourth quarter has always been a good one for biotech and so there is every reason to believe that it is on target to make up for the beating suffered during the first two quarters of 2006. The biotech industry’s aggregate market cap at the end of October was just over $488.0 billion and, by the end of the year, it could reach a new record high,” he stated.
The Burrill Biotech Select Index posted another solid gain of 6% this month, well ahead of the Nasdaq (up 4.8%) and the Dow.
Burrill Small-Cap Biotech Index
Over two thirds of the companies recorded healthy gains, which helped the group move into positive territory on a year-to-date basis. Heading the gainers was Pharmos Corp (up 28%). The company acquired Vela Pharmaceuticals, whose most advanced drug – dextofisopam – is in Phase II clinical trials for the treatment of irritable bowel syndrome. Also chipping in was Monogram Biosciences (up 21%) and Osteotech (up 26%).
RNAi and Why It’s Hot
The rapid and widespread adoption of the RNAi as a research tool has unleashed more demands for funding to capitalize on these advances. There’s already a lag between RNAi’s discovery and the funding to support its use in experiments that also use the genome sequence. The genome sequence, which identified the 30,000 genes that make up the human genetic code, is like a map for unexplored territory and RNAi provides a way to get to places on the map.
RNA interference is used to regulate gene expression in the cells of humans. Hundreds of genes in our genome encode small RNA molecules called microRNAs. They contain pieces of the code of other genes. Such a microRNA molecule can form a double-stranded structure and activate the RNA interference machinery to block protein synthesis. The expression of that particular gene is silenced. Genetic regulation by microRNAs plays an important role in the development of the organism and the control of cellular functions.
RNAi has already become an important research tool in biology and biomedicine. In the future, it is hoped that it will be used in many disciplines including clinical medicine and agriculture. Several recent publications show successful gene silencing in human cells and experimental animals. For instance, a gene causing high blood cholesterol levels was recently shown to be silenced by treating animals with silencing RNA. Plans are underway to develop silencing RNA as a treatment for virus infections, cardiovascular diseases, cancer, endocrine disorders and several other conditions.
SOURCE: GeneThera, Inc., Pharma Market Letter, Knobias, National Institute of Health , Pharma Market Letter, Knobias, National Institute of Health CONTACT: GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.netGeneThera and the Road to Italy/on the Road to Italy Dr. Tony Milici
Chairman of the Board, President & CEO
Source:
GTHA – GeneThera, Inc.
Dr. Antonio Milici, CEO
GeneThera, Inc.
3930 Youngfield St.
Wheat Ridge, CO 80033
Fax: (303) 463 – 6377
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.